Gold Cross marks ‘new era’

With iNova Pharmaceuticals’ recent acquisition of Gold Cross products, a ‘new era of collaboration’ is ushered in with the iconic range to expand into international markets.
This according to the Pharmacy Guild of Australia means new opportunities for the made-in-Australia, exclusively supported and endorsed Guild range. The range includes more than 50 pharmacy-only health products that Australians have turned to for more than 50 years.
Although iNova has distributed the Gold Cross range for several years, CEO, Dan Spira believes the recent acquisition will allow iNova and the Guild to more effectively adapt and promote the portfolio. He also believes the range has untapped potential in Asia, where there is a strong demand for established, Australian-manufactured
brands.
“We are excited about the opportunity to work directly with the Guild to enhance and expand this iconic range of products,” Mr Spira said. “The iNova team is currently reviewing and refreshing the range to optimise the portfolio for a new generation of consumers. We want to work with Guild to re-build the presence of this range in pharmacy.
“iNova also has a growing presence in Asia, and we believe the Gold Cross range will be embraced by Asian consumers.”
Pharmacy Guild of Australia National President George Tambassis believes the new partnership marks a fresh start for Gold Cross brand: “Our partnership with iNova Pharmaceuticals represents an exciting turning point in the portfolio’s history. The Guild is very optimistic about the partnership with iNova and the new opportunities it presents for the Gold Cross brand”.
All sales of Gold Cross-branded products directly assist the Guild. “The income we receive for the use of the Gold Cross branding will continue to be put back into supporting the Guild to promote community pharmacy, particularly in developing new initiatives and expanding the role of pharmacists,” Mr Tambassis said.

Must Read

New regional roadmaps for prioritising antimicrobial resistance

0
A new publication by the International Pharmaceutical Federation (FIP) identifies priority actions pharmacists should take to minimise antimicrobial resistance (AMR). The publication presents six...